BioSpace News Archive

The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock January 28, 2021.

Nateglinide is an oral antihyperglycemic agent. It belongs to the meglitinide class of short-acting insulin secretagogues.

The global mice model market is expanding on account of the striking relevance of these models in performing biomedical research.

BetterLife Pharma Inc., an emerging biotech company focused on the development and commercialization of cutting-edge treatments in mental disorders and viral infections, announces it has entered into an agreement with Eurofins Discovery for TD-0148A’s U.S. FDA Investigational New Drug -enabling pharmacology studies.

ImaginAb Inc, a leading global provider of immuno-oncology imaging agents and NEUVOGEN, an immuno-oncology company developing next generation therapeutic whole cell cancer vaccines, announced they have signed a multi-year non-exclusive licensing agreement.

The trial is designed to replicate previous findings of pridopidine demonstrating maintenance of functional capacity in early HD patients and could lead to the registration of pridopidine

Completes $77 million debt-for-equity exchange with Series C noteholders and senior secured lenders at premiums of 60% and 30% to the 5 day VWAP

A separate study in healthy volunteers demonstrated comparable treprostinil exposure between Tyvaso DPI and Tyvaso Inhalation Solution

Athersys, Inc., a regenerative medicine company developing MultiStem® cell therapy, announced that the Company will host a virtual investor day on Tuesday, February 16, 2021, beginning at 11:00 AM EST.

Kintor Pharmaceutical Limited (HKEX: 9939) is pleased to announce that the clinical trial (the “Trial”) of Proxalutamide’s treatment of hospitalized COVID-19 patients was approved by the Institutional Review Board (“IRB”) of Brazil .